First Horizon Advisors, Inc. Cytokinetics Inc Transaction History
First Horizon Advisors, Inc.
- $3.55 Billion
- Q4 2024
A detailed history of First Horizon Advisors, Inc. transactions in Cytokinetics Inc stock. As of the latest transaction made, First Horizon Advisors, Inc. holds 332 shares of CYTK stock, worth $14,568. This represents 0.0% of its overall portfolio holdings.
Number of Shares
332
Previous 179
85.47%
Holding current value
$14,568
Previous $9,000
66.67%
% of portfolio
0.0%
Previous 0.0%
Shares
12 transactions
Others Institutions Holding CYTK
# of Institutions
397Shares Held
122MCall Options Held
3.46MPut Options Held
1.86M-
Black Rock Inc. New York, NY14.7MShares$644 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.9MShares$523 Million0.01% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD10.8MShares$472 Million0.31% of portfolio
-
Wellington Management Group LLP Boston, MA7.89MShares$346 Million0.07% of portfolio
-
State Street Corp Boston, MA6.17MShares$271 Million0.01% of portfolio
About CYTOKINETICS INC
- Ticker CYTK
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 94,144,096
- Market Cap $4.13B
- Description
- Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates i...